z-logo
HomeZAIABlog
open-access-imgOpen Access
Belimumab
Author(s) -
Urspeter Masche
Publication year - 2014
Publication title -
pharma-kritik
Language(s) - German
Resource type - Journals
SCImago Journal Rank - 0.101
H-Index - 2
ISSN - 1010-5409
DOI - 10.37667/pk.2014.930
Subject(s) - belimumab , political science , gynecology , humanities , medicine , philosophy , antibody , b cell activating factor , immunology , b cell
Belimumab ist das erste Biologikum zur Behandlung des systemischen Lupus erythematodes. Gemäss den bisherigen Erfahrungen verspricht es aber keine überragende Wirkung, und zudem ist es bei den schweren Krankheitsformen mit Nieren- oder ZNS-Beteiligung nicht untersucht.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

AboutCareersPublisher PartnersContact UsGet Organisational Trial or Quote

Learn

FAQsBlogTerms of UsePrivacy Policy

Download the Zendy App

Get it on
Google Play
Download on the
App Store

Discover

Explore

Copyright Knowledge E © 2026. All Rights Reserved.